Quick Hits

Chronic hepatitis C is the most common cause of hepatocellular carcinoma (HCC) in the United States and Europe. Antiviral therapy against hepatitis C virus (HCV) has long been regarded as one of the most effective chemopreventive strategies for HCC. Sustained viral response (SVR) in patients without cirrhosis can halt disease progression, thereby decreasing the risk […]

Quick Hits

Epidemiology. Recent data from the U.S. Cancer Statistics registry show that hepatocellular carcinoma (HCC) continues to rise albeit at a slower rate recently (4.5 percent increase annually from 2000 to 2009, and 0.7 percent from 2010 to 2012). Men between 55 and 64 years of age, Hispanics and, at state-level, Texans, are the most commonly […]

Quick Hits

The advent of direct acting antivirals (DAAs) in the treatment of chronic hepatitis C infection has been revolutionary in that they have drastically mitigated the side effects of therapy while enhancing efficacy relative to interferon-based therapy. DAAs are broadly categorized into the NS3/4A protease inhibitors, NS5A inhibitors, and the non-nucleoside and nucleotide NS5B inhibitors. Ribavirin, […]

Quick Hits

Evidence from a few randomized trials and multiple observational studies supports performing a liver ultrasound every six months as part of hepatocellular carcinoma (HCC) surveillance in patients with hepatitis C virus-related cirrhosis (HCVc). Although the possibility of using other technical modalities is tempting, there are concerns regarding radiation exposure and cost. Use of multiphase computed […]

Liver Bingo Card
Quick Hits

The supply of deceased-donor organs in the U.S. is dwarfed by the demand for lifesaving transplants. Thus, transplant physicians are charged with the responsibility of efficiently allocating these scarce resources. However, when a deceased donor becomes available, not all organs are allocated in the same manner. The Lung Allocation Score prioritizes waitlisted candidates according to […]